A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Leukemia, Myeloid, Acute · Leukemia, Lymphocytic, Acute · Multiple Myeloma · Myelodysplastic Syndromes

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

Hoag Family Cancer Center, Newport Beach, California, United States
Contact: Study coordinator (Benjamin Goldenson, MD) · benjamin.goldenson@hoag.org
Contact: Principal Investigator (Benjamin Goldenson, MD)
Stanford University, Palo Alto, California, United States
Contact: Study coordinator (Gabriel Mannis, MD) · gmannis@stanford.edu
Colorado Blood Cancer Institute, Denver, Colorado, United States
Contact: Study coordinator (Alireza Eghtedar, MD) · alireza.eghtedar@healthonecares.com · 720-754-4800
Contact: Principal Investigator (Alireza Eghtedar, MD)
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States
Contact: Study coordinator (SMPA Investigative Site) · 508-481-6700
University of Miami, Miami, Florida, United States
Contact: Study coordinator (Justin Watts, MD) · jxw401@miami.edu · 305-243-8986
Contact: Principal Investigator (Justin Watts, MD)
Miami Cancer Institute, Miami, Florida, United States
Contact: Study coordinator (SMPA Investigative Site) · 508-481-6700
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Study coordinator (SMPA Investigative Site) · 508-481-6700
Northwestern, Chicago, Illinois, United States
Contact: Study coordinator (Yasmin Abaza, MD) · yasmin.abaza@nm.org
Contact: Principal Investigator (Yasmin Abaza, MD)
Sibley Memorial Hospital, Baltimore, Maryland, United States
Contact: Study coordinator (Mark Levis, MD) · levisma@jhmi.edu
Contact: Principal Investigator (Mark Levis)
University of Maryland, Baltimore, Maryland, United States
Contact: Study coordinator (Maria Baer, MD) · mbaer@umm.edu
Contact: Principal Investigator (Maria Baer, MD)
Johns Hopkins Main Center, Baltimore, Maryland, United States
Contact: Study coordinator (Mark Levis, MD) · levisma@jhmi.edu
Contact: Principal Investigator (Mark Levis, MD)
Tufts University, Boston, Massachusetts, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Study coordinator (Andrew Brunner, MD) · abrunner@mgb.org
Contact: Principal Investigator (Andrew Brunner, MD)
Atlantic Health, Morristown, New Jersey, United States
Contact: Study coordinator (Mohamad Cherry, MD) · mohamad.cherry@atlantichealth.org
Contact: Principal Investigator (Mohamad Cherry, MD)
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Contact: Study coordinator (Neil Palmisiano, MD) · np938@cinj.rutgers.edu
Contact: Principal Investigator (Neil Palmisiano, MD)
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Contact: Study coordinator (Eunice Wang, MD) · Eunice.Wang@RoswellPark.org
Contact: Principal Investigator (Eunice Wang, MD)
Mount Sinai Hospital, New York, New York, United States
Columbia University, New York, New York, United States
UNC Hospital, Chapel Hill, North Carolina, United States
Contact: Study coordinator (Joshua Zeidner, MD) · joshua_zeidner@med.unc.edu
Contact: Principal Investigator (Joshua Zeidner, MD)
Duke University, Durham, North Carolina, United States
Contact: Study coordinator (Harry Erba, MD) · harry.erba@duke.edu · 919-684-8964
Contact: Principal Investigator (Harry Erba, MD)
Atrium Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
Contact: Study coordinator (Timothy Pardee, MD) · tspardee@wakehealth.edu
Contact: Principal Investigator (Timothy Pardee, MD)
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Contact: Study coordinator (Kristen Browning, MD) · Kristen.Browning@osumc.edu
Contact: Principal Investigator (Kristen Browning, MD)
Oncology Associates of Oregon, Eugene, Oregon, United States
Contact: Study coordinator (Luke Fletcher, MD) · luke.fletcher@usoncology.com
Contact: Principal Investigator (Luke Fletcher, MD)
Sidney Kimmel Comprehensive Cancer Center, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Gina Keiffer, MD) · gina.keiffer@jefferson.edu
Contact: Principal Investigator (Gina Keiffer, MD)
Allegheny Health Network, Pittsburgh, Pennsylvania, United States
Contact: Study coordinator (Salman Fazal, MD) · salman.fazal@ahn.org
Contact: Principal Investigator (Salman Fazal, MD)
Medical University of South Carolina, Charleston, South Carolina, United States
Contact: Study coordinator (Praneeth Baratam, MD) · baratamp@musc.edu
Contact: Principal Investigator (Praneeth Baratam, MD)
TriStar Centennial Medical Center, Nashville, Tennessee, United States
Contact: Study coordinator (Stephen Strickland, MD) · Stephen.Strickland@hcahealthcare.com
Contact: Principal Investigator (Stephen Strickland, MD)
MDACC, Houston, Texas, United States
Contact: Study coordinator (Naval Daver, MD) · NDaver@mdanderson.org · 7137944392
Contact: Principal Investigator (Naval Daver, MD)
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Contact: Study coordinator (Paul Shami, MD) · paul.shami@utah.edu
Contact: Principal Investigator (Paul Shami, MD)
Intermountain Healthcare, Salt Lake City, Utah, United States
Contact: Study coordinator (Bradley Hunter, MD) · brad.hunter@imail.org
Contact: Principal Investigator (Bradley Hunter, MD)
University of Virginia, Charlottesville, Virginia, United States
Contact: Study coordinator (Michael Keng, MD) · mk2pv@uvahealth.org
Contact: Principal Investigator (Michael Keng, MD)
Virginia Cancer Specialists, Fairfax, Virginia, United States
Contact: Study coordinator (Mitul Gandhi, MD) · mitul.gandhi@usoncology.com
Contact: Principal Investigator (Mitul Gandhi, MD)
Virginia Oncology Associates, Norfolk, Virginia, United States
Contact: Study coordinator (Celeste Bremer, MD) · celesteann.bremer@usoncology.com
Contact: Principal Investigator (Celeste Bremer, MD)
ZNA Cadix, Antwerp, Belgium
Contact: Study coordinator (Dimitri Breems, MD) · dimitri.breems@zna.be
UZ Ghent, Ghent, Belgium
Contact: Study coordinator (Anke Delie, MD) · anke.delie@uzgent.be
Contact: Principal Investigator (Ine Moors, MD)
University Hospitals Leuven, Leuven, Belgium
Contact: Study coordinator (Johan Maertens, MD) · johan.maertens@uzleuven.be
Contact: Principal Investigator (Johan Maertens, MD)
AZ Delta, Roeselare, Belgium
Contact: Study coordinator (Dries Deeren, MD) · dries.deeren@azdelta.be
Contact: Principal Investigator (Dries Deeren, MD)
Tom Baker Cancer Center, Calgary, Alberta, Canada
Contact: Study coordinator (Lynn Savoie, MD) · lynn.savoie@albertahealthservices.ca
Contact: Principal Investigator (Lynn Savoie, MD)
University of Alberta, Edmonton, Canada
Contact: Study coordinator (Joseph Brandwein, MD) · jbrandwe@ualberta.ca
Contact: Principal Investigator (Joseph Brandwein, MD)
Centre Hospitalier Universitaire d'Angers, Angers, France
Contact: Study coordinator (Corentin Orvain, MD) · corentin.orvain@chu-angers.fr
Contact: Principal Investigator (Corentin Orvain, MD)
Hopital Avicenne, Bobigny, France
Contact: Study coordinator (Ramy Rahme, MD) · ramy.rahme@aphp.fr
Centre Hospitalier Le Mans, Le Mans, France
Contact: Study coordinator (Kamel Laribi, MD) · klaribi@ch-lemans.fr
Hopital Claude Huriez, Lille, France
Contact: Study coordinator (Celine Berthon, MD) · celine.berthon@chu-lille.fr
Centre Hospitalier Universitaire de Limoges, Limoges, France
Contact: Study coordinator (Pascal Turture, MD) · Pascal.Turlure@chu-limoges.fr
Hospices Civils de Lyon, Lyon, France
Contact: Study coordinator (Mael Heiblig, MD) · mael.heiblig@chu-lyon.fr
Institut Paoli-Calmettes, Marseille, France
Contact: Study coordinator (Sylvain Garciaz, MD) · garciazs@ipc.unicancer.fr
Contact: Principal Investigator (Sylvain Garciaz, MD)
CHU de Nantes, Nantes, France
Contact: Study coordinator (Pierre Peterlin, MD) · Pierre.PETERLIN@chu-nantes.fr
CHU de Nice - Hôpital l'Archet 1, Nice, France
Contact: Study coordinator (Thomas Cluzeau, MD) · cluzeau.t@chu-nice.fr
Contact: Principal Investigator (Thomas Cluzeau, MD)
Hopital Saint-Louis, Paris, France
Contact: Study coordinator (Emmanuel Raffoux, MD) · emmanuel.raffoux@aphp.fr
Contact: Principal Investigator (Emmanuel Raffoux, MD)
CHU Bordeaux, Talence, France
Contact: Study coordinator (Arnaud Pigneux, MD) · Arnaud.pigneux@chu-bordeaux.fr
Institut Gustave Roussy, Villejuif, France
Contact: Study coordinator (Stephane Debotton, MD) · Stephane.DEBOTTON@gustaveroussy.fr
IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Policlinico Sant'Orsola, Bologna, Italy
Contact: Study coordinator (Cristina Papayannidis, MD)
Contact: Principal Investigator (Cristina Papayannidis, MD)
Ospedale di Busto Arsizio, Busto Arsizio, Italy
Contact: Study coordinator (Elisabetta Todisco, MD) · elisabetta.todisco@asst-valleolona.it
Ospedale Policlinico San Martino, IRCCS, Genoa, Italy
Contact: Study coordinator (Marica Laurino, MD) · maurica.laurino@hsanmartino.it
IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori", Meldola, Italy
Contact: Study coordinator (Maria Giannini, MD) · Maria.giannini@irst.emr.it
Istituto Oncologico Veneto (IOV), IRCCS, Padua, Italy
Contact: Study coordinator (Michele Gottardi, MD) · michele.gottardi@iov.it
Università degli Studi di Perugia, Perugia, Italy
Contact: Study coordinator (Maria Martelli, MD) · maria.martelli@unipg.it
Azienda USL della Romagna, Ospedale Santa Maria delle Croci di Ravenna, Ravenna, Italy
Contact: Study coordinator (Giovanni Marconi, MD) · giovanni.marconi2@unibo.it
PU A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy
Contact: Study coordinator (Patrizia Chiusolo, MD) · Patrizia.Chiusolo@Unicatt.it
Universita' Degli Studi Di Torino, Turin, Italy
Contact: Study coordinator (Benedetto Bruno, MD) · benedetto.bruno@unito.it
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Contact: Study coordinator (Junichiro Yuda) · jyuda@east.ncc.go.jp · +81-4-7133-1111
Contact: Principal Investigator (Junichiro Yuda, MD)
University of Fukui Hospital, Yoshida-gun, Fukui, Japan
Contact: Study coordinator (Naoko Hosono) · hosono@u-fukui.ac.jp · +81-776-61-3111
Contact: Principal Investigator (Naoko Hosono, MD)
Fukushima Medical University Hospital, Fukushima, Fukushima, Japan
Contact: Study coordinator (Takayuki Ikezoe) · ikezoet@fmu.ac.jp · +81-24-547-1111
Contact: Principal Investigator (Takayuki Ikezoe, MD)
Tokai University Hospital, Isehara-shi, Kanagawa, Japan
Contact: Study coordinator (Yoshiaki Ogawa) · yoshioga@is.icc.u-tokai.ac.jp · +81-463-93-1121
Contact: Principal Investigator (Yoshiaki Ogawa, MD)
Nagasaki University Hospital, Nagasaki, Nagasaki, Japan
Contact: Study coordinator (Yasushi Miyazaki) · y-miyaza@nagasaki-u.ac.jp · +81-95-819-7200
Contact: Principal Investigator (Yasushi Miyazaki, MD)
Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan
Contact: Study coordinator (Hiroki Yamaguchi, MD) · y-hiroki@fd6.so-net.ne.jp · +81-3-3822-2131
Contact: Principal Investigator (Hiroki Yamaguchi, MD)
Tokyo Metropolitan Komagome Hospital, Bunkyō City, Japan
Contact: Study coordinator (Tomomi Toubai, MD) · tomomi_tobai@tmhp.jp
Kyushu University Hospital, Fukuoka, Japan
Contact: Study coordinator (Takahiro Shima, MD) · shima.takahiro.993@m.kyushu-u.ac.jp · 81-92-641-1151
Contact: Principal Investigator (Takahiro Shima, MD)
Hokkaido University Hospital, Hokkaido, Japan
Contact: Study coordinator (Takanori Teshima, MD) · teshima@med.hokudai.ac.jp · +81-11-716-1161
Contact: Principal Investigator (Takanori Teshima, MD)
Tohoku University Hospital, Miyagi, Japan
Contact: Study coordinator (Koichi Onodera, MD) · koichi.onodera.d6@tohoku.ac.jp · +81-22-717-7165
Contact: Principal Investigator (Hisayuki Yokoyama, MD)
Okayama University Hospital, Okayama, Japan
Contact: Study coordinator (Noboru Asada, MD) · nasada@okayama-u.ac.jp · +81-86-223-7151
Contact: Principal Investigator (Noboru Asada, MD)
Osaka University Hospital, Osaka, Japan
Contact: Study coordinator (Kentaro Fukushima, MD) · kfukushi@bldon.med.osaka-u.ac.jp · +81-6-6879-5111
Contact: Principal Investigator (Kentaro Fukushima, MD)
National University Cancer Institute, Singapore, Singapore
Contact: Study coordinator (Melissa Ooi, MD) · melissa_ooi@nuhs.edu.sg
Contact: Principal Investigator (Melissa Ooi, MD)
Chonnam National University Hwasun Hospital, Hwasun, South Korea
Contact: Study coordinator (Jae-Sook Ahn, MD) · f0115@jnu.ac.kr
Contact: Principal Investigator (Jae-Sook Ahn, MD)
Samsung Medical Center, Seoul, South Korea
Contact: Study coordinator (Dahee Jung) · ddahee.jung@samsung.com
Contact: Principal Investigator (Jun Jo Hang, MD)
Seoul National University Hospital, Seoul, South Korea
Contact: Study coordinator (Juhyun Lee) · leejh8368@snuh.org
Contact: Principal Investigator (Dong-Yeop Shin, MD)
The Catholic University of Korea, Seoul, South Korea
Contact: Study coordinator (HeeJe Kim, MD) · cumckim@catholic.ac.kr
Contact: Principal Investigator (HeeJe Kim, MD)
Hospital General Universitario De Albacete, Albacete, Spain
Contact: Study coordinator (Jesus Lorenzo Algarra, MD) · jlalgarra@sescam.jccm.es
Contact: Principal Investigator (Jesus Lorenzo Algarra, MD)
Hospital Universitari Vall D'Hebron, Barcelona, Spain
Contact: Study coordinator (Olga Garcia, MD) · osalamero@vhio.net
Institut Catala d'Oncologia, Barcelona, Spain
Contact: Study coordinator (Susana Vives Polo, MD) · svives@iconcologia.net
Contact: Principal Investigator (Susana Vives Polo, MD)
Hospital San Pedro de Alcantara, Cáceres, Spain
Contact: Study coordinator (Juan Miguel Bergua Burgues) · jmberguaburg@gmail.com
Contact: Principal Investigator (Juan Miguel Bergua Burgues, MD)
Hospital Universitario De Gran Canaria Dr. Negrin, Las Palmas, Spain
Contact: Study coordinator (Carlos Rodriguez Medina, MD) · crodmedk@gobiernodecanarias.org
Contact: Principal Investigator (Carlos Rodriguez Medina, MD)
MD Anderson Cancer Center, Madrid, Spain
Contact: Study coordinator (Adolfo de la Fuente Burguera, MD) · afuente@mdanderson.es
Contact: Principal Investigator (Adolfo de la Fuente Burguera, MD)
Hospital Universitario Central De Asturias, Oviedo, Spain
Contact: Study coordinator (Teresa Bernal del Castillo, MD) · bernaldelcastillo@gmail.com
Contact: Principal Investigator (Teresa Bernal del Castillo, MD)
Hospital Universitario de Salamanca, Salamanca, Spain
Contact: Study coordinator (Maria-Belen Vidriales Vicente, MD) · mbvidri@usal.es
Contact: Principal Investigator (Maria-Belen Vidriales Vicente, MD)
Fundacion Instituto de Investigacion Marques de Valdecilla, Santander, Spain
Contact: Study coordinator (Guillermo Sanchez) · guillermo.martin@scsalud.es
Complexo Hospitalario Universitario De Santiago, Santiago de Compostela, Spain
Contact: Study coordinator (Manual Perez, MD) · manualmateo.perez@usc.es
Hospital Universitario y Politecnico La Fe, Valencia, Spain
Contact: Study coordinator (Pau Montesinos, MD) · montesinos_pau@gva.es
Contact: Principal Investigator (Paul Montesinos, MD)
University Hospital Basel, Basel, Switzerland
University Hospital Bern Inselspital, Bern, Switzerland
Universitaetsspital Zuerich - Haematology, Zurich, Switzerland
Taichung Veterans General Hospital, Taichung, Taiwan
Contact: Study coordinator (Huey-En Tzeng, MD) · tzenghueyen@gmail.com
Contact: Principal Investigator (Huey-En Tzeng, MD)
National Cheng Kung University Hospital, Tainan, Taiwan
Contact: Study coordinator (Tsai-Yun Chen, MD) · teresa@mail.ncku.edu.tw
Contact: Principal Investigator (Tsai-Yun Chen, MD)
National Taiwan University Hospital, Taipei, Taiwan
Contact: Study coordinator (Yi Hsuan Shao) · bakeyshao248@gmail.com
Contact: Principal Investigator (Shang-Ju Wu, MD)
University Hospitals of Birmingham Centre for Clinical Hematology, Birmingham, United Kingdom
Contact: Study coordinator (Vidya Murthy) · vidhya.murthy2@uhb.nhs.uk
Bristol Hematology & Oncology Centre, Bristol, United Kingdom
Contact: Study coordinator (Katharine Hodby, MD) · katharine.hodby@uhbw.nhs.uk
NHS Lothian Western General, Edinburgh, United Kingdom
Contact: Study coordinator (Victoria Campbell, MD) · victoria.campbell15@nhs.scot
King's College Hospital, London, United Kingdom
Contact: Study coordinator (Pramila Krishnamurthy, MD) · pramila.krishnamurthy@kcl.ac.uk
Sarah Cannon Research Institute, London, United Kingdom
Contact: Study coordinator (Richard Dillon, MD) · richard.dillon@kcl.ac.uk
University College London Hospitals NHS Foundation Trust, London, United Kingdom
Contact: Study coordinator (Jenny O'nions, MD) · jenny.o'nions@nhs.net
Christie Hospital NHS Foundation Trust, Manchester, United Kingdom
Contact: Study coordinator (Emma Searle, MD) · emma.searle9@nhs.net
Churchill Hospital Oxford, Oxford, United Kingdom
Contact: Study coordinator (Connor Sweeney) · connor.sweeney@hee.nhs.uk
University Hospitals of North Midlands NHS Foundation Trust, Stoke-on-Trent, United Kingdom
Contact: Study coordinator (Srinivas Pillai, MD) · Srinivas.pillai@uhnm.nhs.uk
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Contact: Study coordinator (David Taussig, MD) · david.taussig@rmh.mhs.uk

צפייה במקור ב־ClinicalTrials.gov

ניסויים דומים

ניסויים נוספים שמגייסים כעת ועשויים להיות רלוונטיים לפי מצב רפואי, טיפול, שלב או מיקום

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Acute Myeloid Leukemia in Remission · Myelodysplastic Syndromes · Chronic Myeloid Leukemia in Remission

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

Antwerp, Belgium · Bruges, Belgium

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Myelodysplastic Syndromes · Acute Myeloid Leukemia · Myelodysplastic Syndrome/Neoplasm

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2, PHASE3

Los Angeles, United States · Orange, United States

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Lymphocytic Leukemia

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2

Duarte, United States · Atlanta, United States

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Hematologic Malignancy · Non Hodgkin Lymphoma · Acute Myeloid Leukemia

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

Tianjin, China